Skip To Main Content
Q. Barry on Muck Rack

Q. Barry

As seen in: Canadian Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Q.

Contact Q., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

QUANTIFYING THE NEED FOR MICROAXIAL-FLOW PUMP IN STEMI SHOCK PATIENTS: DATA FROM A LARGE CANADIAN QUATERNARY CENTER

|
By R. Boudreau, N. Malhotra, C. A. Clifford, Q. Barry, M. Laverdure, W. Knoll, A. Chong, M. R. Le May, D. Y. So
| Canadian Journal of Cardiology Verified
Cardiogenic shock in patients with ST-Elevation MI (STEMI) confers a mortality of up to 50%. The recent DanGer trial, using a strategy of temporary mechanical circulatory support with a microaxial-flow pump, was associated with an absolute reduction in mortality of 12.7%. Notable is the highly selective nature of the patients included in the trial and the substantial resources required, including devices and lengthened hospital and intensive care stays.
Open in Who Shared Issue with article?

OUTCOMES OF APPROPRIATE VERSUS INAPPROPRIATE DE-ESCALATION OF P2Y12 INHIBITOR THERAPY POST PERCUTANEOUS CORONARY INTERVENTION: A RETROSPECTIVE COHORT STUDY.

|
By Q. Barry, A. Fu, R. Boudreau, D. Perry-Nguyen
| Canadian Journal of Cardiology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Current guidelines recommend ticagrelor or prasugrel as first-line agents for patients with acute coronary syndromes (ACS). While de-escalation from ticagrelor or prasugrel to clopidogrel is common practice, this may be considered “inappropriate” when a change between potent agents is an option. This practice may put patients at risk of ischemic complications.
Open in Who Shared Issue with article?

INCIDENCE AND RATIONALE FOR P2Y12 INHIBITOR SWITCHING IN PATIENTS WITHIN 1 YEAR OF PERCUTANEOUS CORONARY INTERVENTION

|
By A. Fu, Q. Barry, R. Boudreau, D. Perry-Nguyen
| Canadian Journal of Cardiology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresDual antiplatelet therapy (DAPT), with aspirin and a P2Y12 inhibitor, is the standard therapy for patients with acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI). Clopidogrel has traditionally been the P2Y12 agent of choice.
Open in Who Shared Issue with article?
See all 5 articles